This document summarizes SmartFreez's cryopreservation solutions for cell and protein therapies. It outlines the problems with current cryopreservation tools, SmartFreez's solutions to improve cell and protein viability during freezing and storage, and their product portfolio. SmartFreez has generated revenue working with top pharmaceutical companies and is seeking 2 million euros to further develop its products, expand patent protection, and market its solutions globally to biopharmaceutical and medical companies. Its founders currently own 100% equity and it has potential exit strategies through acquisition of different parts of the business by 2022 and 2027.

1. Precision cryosystems for precise medicines
Lisbon, March16th 2017

2. PROBLEM
Lack of Effective Cryopreservation Tools to make Cell and
Protein based therapies viable and available for everybody.

3. TRACTION
SmartFreez has been requested by a few of the Top 10 Pharma Players, and has been
generating revenues in the last 18 months:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Designing and providing cryopreservation systems:
Watch the vídeo at: http://smartfreez.com/solutions/computational-
fluid-dynamics/

4. SOLUTION
Problems: Solutions:
Cell low survival rate
Use of toxic
cryopreservatives (DMSO)
Unstandardized
freeze-thawing procedures
Cryopreservation method
design
Inconsistent
freezing
CellsProteins
SmartCryo - Cells 1
(for the Lab &
Research Market)
SmartCryo - Cold
Stability Accelerator
SmartCryo - Cube
(small and large
scale)
SmartCryo - Cells 2
(Medical Device)
US made Cryocube unit
complying with pharma
industry standards
Protein Stability Study
tool to replicate in a
few weeks the freezing
pattern of years!
Better performance on cell
cryopreservation vs
the major competitor
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12
Funtionalproteinfraction
Storage time, weeks

5. MARKET & COMPETITION
Market Competition
Biopreservation Global Market – a strong and
fast growing sector!
2015 2024 CAGR
$3Bn $9.7Bn 13.4%
Cell
Cryopreservation
Protein
Cryopreservation
Safety
SmartCryo
Cells
Quality- + Quality- +
SmartCryo
Cube
Bio-
cision
Asymp
-tote
Zeta
Sarto
-rius
+

6. TEAM
Miguel Rodrigues – PhD, CEO
– Expert in Pharmaceutical Engineering –
thermodynamics and cryogenic technologies.
– More than 10 years of experience enhancing
stability and delivery of pharmaceutical
substances.
Vitor Geraldes – PhD, CTO
– Expert in process engineering, transport
phenomena and computational methods.
– More than 15 years of experience modelling
and developing systems for food and medical
industry
Rui Estrela – MBA, COO
– Expertise in Marketing, Financial Controlling
and Business Development
– More than 15 years of experience national and
multi-national companies (BDO Binder, F. Lima,
Reckitt Benckiser).
Pedro Rego – MSc, Research Engineer
– Specialised on CFD, cryopreservation of
unicelular organisms and experimental
scientific projects.
– Expert in experimental models and prototyping
for low temperatures.
Andreia Duarte – PhD, Research Scientist
– Graduation in Biochemistry and PhD in
Biomedicine.
– Experience in protein aggregation studies,
microbiology and cell related research.

7. BUSINESS MODEL
KEY ACTIVITIES
• Technology and
Quality Control
• New Product
Development
KEY ACTIVITIES
• Manufacturing
partners
• Distribution
partners
KEY PARTNERS
• R&D
• Engineering
KEY RESOURCES
KEY ACTIVITIES
• Biopharma &
biotech companies
• Hospitals & clinical
treatment centers
CUSTOMER SEGMENTS
• Global Distributors
CHANNELS
• Equipment sales
revenues
REVENUE MODEL

8. GOALS & MILESTONES
Next 15 Months:
Q3
2017
Q4
2017
Q1
2018
Q2
2018
Q3
2018
* Expand
IP/Patent
Protection
*Finalize Cold Stability
Accelerator & SmartCryo
Cells pilot equipment
(complying with standards)
*Pilot testing of SmartCryo
Cube in a relevant biopharma
player and publishing of
results
* Pilot testing of
Cold Stability
Accelerator &
SmartCryo
Cells with
relevant players
* Global
Launch of
SmartCryo
Cube
* Global launch of
Cold Stability
Accelerator &
SmartCryo Cells
(in lab & research
market)

9. BUSINESS MODEL
1. Miguel Rodrigues
2. Vitor Geraldes
3. Rui Estrela
The original founders still own 100%
of SmartFreez’s equity
Equity Owners:

10. FUND RAISING & USE OF PROCEEDS
Total Funds Needed: 2M€
Use of Proceeds:
1. Product Development: 550 K€
2. Patent Protection and Legal: 250 K€
3. Regulatory Diligences: 500 K€
4. Marketing/Scaling: 480 K€
5. Working Capital: 220 K€
TOTAL 2 000 K€

11. EXIT STRATEGY
Potential
Buyers:
Sale of
Business
Areas:
2022
Cold Stability Accelerator SmartCryo - Cube
Analytical Equipment Player
ex: HP Agilent
Industrial Systems Player
ex: Sartorius,
Pall Corporation
SmartCryo - Cells
2027
Medical Technology Player
ex: GE Healthcare,
Medtronic

12. THANK YOU !
Lisbon, March16th 2017
www.smartfreez.com